Health economic models in hemophilia A and utility assumptions from a clinician's perspective

摘要

BackgroundThe clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following: reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear.